title: [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
authors.forename: T T
authors.initials: TT
authors.lastname: Valiev
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Vinogradova
authors.forename: N G
authors.initials: NG
authors.lastname: Chernova
authors.forename: D S
authors.initials: DS
authors.lastname: Mar'in
authors.forename: Ia K
authors.initials: IaK
authors.lastname: Volkova
authors.forename: V I
authors.initials: VI
authors.lastname: Petrova
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Bulanov
authors.forename: N N
authors.initials: NN
authors.lastname: Kalinin
authors.forename: E A
authors.initials: EA
authors.lastname: Semenova
authors.forename: E M
authors.initials: EM
authors.lastname: Gretsov
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: A I
authors.initials: AI
authors.lastname: Vorob'ev
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000175:diagnosis / Q000188:drug therapy*; D015458:Leukemia, T-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D003520:Cyclophosphamide; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine